Viking Therapeutics Stock News

These two mid-cap biotechs have exciting pipelines. Important breakthroughs could lead to market-beating returns.

Viking Therapeutics has been one of the best-performing biotech stocks over the past three years. Not long ago, however, its shares were down by more than two-thirds from their IPO price and the compa

Investors are excited about Viking's prospects in what may become a $100 billion market. The biotech just reported positive results from a clinical trial of its weight loss drug candidate -- one aimin

Shares of Viking Therapeutics recently rocketed higher in response to positive clinical trial results. Results of a mid-stage trial suggest Viking's weight management candidate can compete strongly wi

This week, Viking Therapeutics reported positive results from phase 2 trial of VK2735 in patients with obesity or overweight patients with a comorbidity. The company is raising $350M, but already had

The biggest bear argument over the past year has been the slim leadership in the market, namely concentrated in mega-cap tech stocks like the "Mag 7." However, dig deeper, and you will discover that t

Viking Therapeutics' Phase II VENTURE trial of VK2735 shows statistically significant decreases in body weight, positioning it as a potential best-in-class therapy for obesity. VK2735 demonstrates pro

Viking Therapeutics (VKTX) soars on weight loss drug trials. Renita Young discusses this as 88% of patients tested achieved at least 10% weight loss.

Biotech stocks have long been a speculative, albeit rewarding way to invest in the advancement of medical technology. This industry has a wide range of companies, from start-up firms that are research

Viking Therapeutics Inc (NASDAQ:VKTX) stock is skyrocketing today, after the biotech's experimental obesity drug helped achieve "significant" weight loss in a mid-stage study.

Viking Therapeutics (NASDAQ: VKTX ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced positive clinical trial results. These results come from its Phase

U.S. stocks opened little changed Tuesday, as traders took a breather before important economic data later in the week, including a closely watched inflation gauge.

Viking Therapeutics (NASDAQ:VKTX) Inc shares skyrocketed almost 80% on Tuesday morning after the firm unveiled positive results from a trial of its VK2735 weight loss drug. Patients receiving the trea

Analysts have suggested that larger pharmaceutical companies could potentially move to acquire a company like Viking Therapeutics.

Patients see ‘significant' reductions in body weight during a study of a weight-loss drug developed by Viking Therapeutics, the company says.